DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Day One exists to help children with cancer, 
from day one and every day after.

Ready  to make an impact
Day One is working hard to bring novel targeted therapies to children with brain cancer and potentially others who can benefit.
Breaking News from Day One Pharma!
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Day One Biopharmaceuticals Pipeline

Day One was born ready.
They're ready to deliver a lasting impact for children with cancer by making sure modern targeted treatments can get to those who need them most.

How? Through their deep understanding of biology and the pediatric community. They have a purposeful approach to drug development. And the right mix of people, experience and skills to drive real lasting change.

They're ready to introduce new ground-breaking treatments. Ready to be dedicated, long-term partners. Ready to solve the challenges faced by children with cancer.
Their Mission
Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new medicines for people of all ages with life-threatening diseases.

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram